Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d'Ivoire

作者：Toure Offianan A^*; Kouame Menan G; Didier Yapi J; Berenger Ako A A; Djerea Khali; Genevieve Gomez O; Penali Louis K

来源：Tropical Medicine and International Health, 2011, 16(3): 290-297.

DOI：10.1111/j.1365-3156.2010.02701.x

• falciparum malaria Artesunate-mefloquine
• Artemether-lumefanthrine
• children
• uncomplicated malaria

OBJECTIVES To test the hypothesis that Artesunate mefloquine paediatric (AS+MEF) is as effective as Artemether lumefantrine (AL) in treating acute uncomplicated malaria in children.
METHODS In an open label, randomized controlled clinical trial, children aged 6-59 months were randomized to receive AS+MEF or AL. Both drug regimens were given for 3 days, and follow-up was for 28 days. The primary endpoint was the 28-day cure rate and was defined as proportion of patients with PCR-corrected cure rate after 28 days of follow-up.
RESULTS One hundred and fifty-six patients with confirmed uncomplicated P. falciparum malaria were randomly assigned to receive AS+MEF (n = 77) or AL (n = 79). PCR-corrected day 28 cure rates for per protocol (PP) populations were 99% for AS+MEF and 97% (P = 1) for AL. For the intention to treat (ITT) population, cure rates were 96% for AS+MEF and 92% (P = 0.49) for AL. Both regimens were well tolerated.
CONCLUSION AS+MEF is as effective as AL, and both combinations were efficacious and safe.

• 出版日期2011-3